Affordable Access

deepdyve-link
Publisher Website

Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan

Authors
  • Okumura, Hiroyuki1
  • Inoue, Sachie2
  • Naidoo, Shevani3
  • Holmstrom, Stefan4
  • Akaza, Hideyuki5
  • 1 Astellas Pharma Inc., Japan , (Japan)
  • 2 CRECON Medical Assessment Inc., Japan , (Japan)
  • 3 Astellas Pharma Inc., UK , (United Kingdom)
  • 4 Astellas Pharma Inc., The Netherlands , (Netherlands)
  • 5 Strategic Investigation on Comprehensive Cancer Network, Japan , (Japan)
Type
Published Article
Journal
Japanese Journal of Clinical Oncology
Publisher
Oxford University Press
Publication Date
May 25, 2021
Volume
51
Issue
8
Pages
1319–1329
Identifiers
DOI: 10.1093/jjco/hyab071
PMID: 34037235
PMCID: PMC8326386
Source
PubMed Central
Keywords
Disciplines
  • AcademicSubjects/MED00300
License
Unknown

Abstract

As a result of a cost-effectiveness analysis, enzalutamide is suggested to be cost-saving versus abiraterone, but less cost-effective than docetaxel, for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in Japan.

Report this publication

Statistics

Seen <100 times